Gene supplementation therapy is hardly feasible in DS, as SCN1A coding sequence largely exceeds the packaging cargo of adeno-associated viral vectors (AAV), that are commonly employed for therapeutic gene delivery in the CNS3,4. This evidence concerns the gene SCN1A and Dravet syndrome.